Top

Published in:

01-09-2015 | Original Paper

Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer’s Disease

Authors: Orestes Vicente Forlenza, Breno Satler Diniz, Antonio Lucio Teixeira, Marcia Radanovic, Leda Leme Talib, Natalia Pessoa Rocha, Wagner Farid Gattaz

Published in: NeuroMolecular Medicine | Issue 3/2015

Abstract

There is little information on the dynamics of BDNF in the CSF in the continuum between healthy aging, MCI and AD. We included 128 older adults (77 with amnestic MCI, 26 with AD and 25 healthy controls). CSF BDNF level was measured by ELISA assay, and AD biomarkers (Aβ₄₂, T-Tau and P-Tau₁₈₁) were measured using a Luminex xMAP assay. CSF BDNF levels were significantly reduced in AD subjects compared to MCI and healthy controls (p = 0.009). Logistic regression models showed that lower CSF BDNF levels (p = 0.008), lower CSF Aβ₄₂ (p = 0.005) and lower MMSE scores (p = 0.007) are significantly associated with progression from MCI to AD. The present study adds strong evidence of the involvement of BDNF in the pathophysiology of neurodegenerative changes in AD. Interventions aiming to restore central neurotrophic support may represent future therapeutic targets to prevent or delay the progression from MCI to AD.

Available only for authorised users

Alvarez, X. A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., et al. (2011). Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology, 18, 59–68.CrossRefPubMed

Angelucci, F., Spalletta, G., di Iulio, F., Ciaramella, A., Salani, F., Colantoni, L., et al. (2010). Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Current Alzheimer Research, 7, 15–20.CrossRefPubMed

Blasko, I., Lederer, W., Oberbauer, H., Walch, T., Kemmler, G., Hinterhuber, H., et al. (2006). Measurement of thirteen biological markers in CSF of patients with Alzheimer’s disease and other dementias. Dementia and Geriatric Cognitive Disorders, 21, 9–15.CrossRefPubMed

Brunoni, A. R., Lopes, M., & Fregni, F. (2008). A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: Implications for the role of neuroplasticity in depression. International Journal of Neuropsychopharmacology, 11, 1169–1180.CrossRefPubMed

Christensen, R., Marcussen, A. B., Wortwein, G., Knudsen, G. M., & Aznar, S. (2008). A beta(1–42) injection causes memory impairment, lowered cortical and serum BDNF levels, and decreased hippocampal 5-HT(2A) levels. Experimental Neurology, 210, 164–171.CrossRefPubMed

Clément, F., & Belleville, S. (2010). Compensation and disease severity on the memory-related activations in mild cognitive impairment. Biological Psychiatry, 68, 894–902. doi:10.1016/j.biopsych.2010.02.004.CrossRefPubMed

Covaceuszach, S., Capsoni, S., Ugolini, G., Spirito, F., Vignone, D., & Cattaneo, A. (2009). Development of a non invasive NGF-based therapy for Alzheimer’s disease. Current Alzheimer Research, 6, 158–170.CrossRefPubMed

de Sousa, R. T., van de Bilt, M. T., Diniz, B. S., Ladeira, R. B., Portela, L. V., Souza, D. O., et al. (2011). Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: A preliminary 4-week study. Neuroscience Letters, 494, 54–56.CrossRefPubMed

Diniz, B. S., & Teixeira, A. L. (2011). Brain-derived neurotrophic factor and Alzheimer’s disease: Physiopathology and beyond. NeuroMolecular Medicine, 13, 217–222.CrossRefPubMed

Diniz, B. S., Reynolds, C. F., I. I. I., Begley, A., Dew, M. A., Anderson, S. J., Lotrich, F., et al. (2014a). Brain-derived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: A longitudinal study. Journal of Psychiatric Research, 49, 96–101.PubMedCentralCrossRefPubMed

Diniz, B. S., Sibille, E., Ding, Y., Tseng, G., Aizenstein, H. J., Lotrich, F., et al. (2015). Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression. Molecular Psychiatry, 20, 594–601. doi:10.1038/mp.2014.76.CrossRefPubMed

Diniz, B. S., Teixeira, A. L., Machado-Vieira, R., Talib, L. L., Radanovic, M., Gattaz, W. F., et al. (2014b). Reduced cerebrospinal fluid levels of brain-derived neurotrophic factor is associated with cognitive impairment in late-life major depression. The Journals of Gerontology Series B: Psychological Sciences and Social Sciences, 69, 845–851.CrossRef

Diniz, B. S., Teixeira, A. L., Talib, L. L., Mendonca, V. A., Gattaz, W. F., & Forlenza, O. V. (2010). Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. World Journal of Biological Psychiatry, 11, 550–555.CrossRefPubMed

Douillard-Guilloux, G., Guilloux, J. P., Lewis, D. A., & Sibille, E. (2013). Anticipated brain molecular aging in major depression. American Journal of Geriatric Psychiatry, 21, 450–460.CrossRefPubMed

Faria, M. C., Gonçalves, G. S., Rocha, N. P., Moraes, E. N., Bicalho, M. A., Cintra, M. T. G., et al. (2014). Increased plasma levels of BDNF and inflammatory markers in Alzheimer’s disease. Journal of Psychiatric Research, 53, 166–172.CrossRefPubMed

Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011). Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. British Journal of Psychiatry, 198, 351–356.CrossRefPubMed

Forlenza, O. V., Diniz, B. S., Talib, L. L., Radanovic, M., Yassuda, M. S., Ojopi, E. B., et al. (2010a). Clinical and biological predictors of Alzheimer’s disease in patients with amnestic mild cognitive impairment. Revista Brasileira de Psiquiatria, 32, 216–222.CrossRefPubMed

Forlenza, O. V., Diniz, B. S., Teixeira, A. L., Ojopi, E. B., Talib, L. L., Mendonca, V. A., et al. (2010b). Effect of brain-derived neurotrophic factor Val66Met polymorphism and serum levels on the progression of mild cognitive impairment. World Journal of Biological Psychiatry, 11, 774–780.CrossRefPubMed

Huijbers, W., Mormino, E. C., Schultz, A. P., Wigman, S., Ward, A. M., Larvie, M., et al. (2015). Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression. Brain, 138, 1023–1035. doi:10.1093/brain/awv007.CrossRefPubMed

Laske, C., Stransky, E., Leyhe, T., Eschweiler, G. W., Maetzler, W., Wittorf, A., et al. (2007). BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. Journal of Psychiatric Research, 41, 387–394.CrossRefPubMed

Li, G., Peskind, E. R., Millard, S. P., Chi, P., Sokal, I., Yu, C. E., et al. (2009). Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS ONE, 4, e5424.PubMedCentralCrossRefPubMed

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology, 34, 939–944.CrossRefPubMed

Miller, S. L., Fenstermacher, E., Bates, J., Blacker, D., Sperling, R. A., & Dickerson, B. C. (2008). Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline. Journal of Neurology, Neurosurgery and Psychiatry, 79, 630–635.PubMedCentralCrossRefPubMed

Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., et al. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nature Medicine, 15, 331–337.PubMedCentralCrossRefPubMed

Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005). Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. Journal of Neurochemistry, 93, 1412–1421.CrossRefPubMed

Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., et al. (2001). Current concepts in mild cognitive impairment. Archives of Neurology, 58, 1985–1992.CrossRefPubMed

Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., & Winslow, J. W. (1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron, 7, 695–702.CrossRefPubMed

Rockenstein, E., Ubhi, K., Pham, E., Michael, S., Doppler, E., Novak, P., et al. (2011). Beneficial effects of a neurotrophic peptidergic mixture persist for a prolonged period following treatment interruption in a transgenic model of Alzheimer’s disease. Journal of Neuroscience Research, 89, 1812–1821.PubMedCentralCrossRefPubMed

Shimada, H., Makizako, H., Doi, T., Yoshida, D., Tsutsumimoto, K., Anan, Y., et al. (2014). A large, cross-sectional observational study of serum BDNF, cognitive function, and mild cognitive impairment in the elderly. Frontiers in Aging Neuroscience, 6, 69.PubMedCentralCrossRefPubMed

Sibille, E. (2013). Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders. Dialogues in Clinical Neuroscience, 15, 53–65.PubMedCentralPubMed

Teixeira, A. L., Barbosa, I. G., Diniz, B. S., & Kummer, A. (2010). Circulating levels of brain-derived neurotrophic factor: Correlation with mood, cognition and motor function. Biomarkers in Medicine, 4, 871–887.CrossRefPubMed

Weinstein, G., Beiser, A. S., Choi, S. H., Preis, S. R., Chen, T. C., Vorgas, D., et al. (2014). Serum brain-derived neurotrophic factor and the risk for dementia: The Framingham heart study. JAMA Neurolology, 71, 55–61.CrossRef

Yu, H., Zhang, Z., Shi, Y., Bai, F., Xie, C., Qian, Y., et al. (2008). Association study of the decreased serum BDNF concentrations in amnestic mild cognitive impairment and the Val66Met polymorphism in Chinese Han. Journal of Clinical Psychiatry, 69, 1104–1111.CrossRefPubMed

Title: Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer’s Disease
Authors: Orestes Vicente Forlenza
Breno Satler Diniz
Antonio Lucio Teixeira
Marcia Radanovic
Leda Leme Talib
Natalia Pessoa Rocha
Wagner Farid Gattaz
Publication date: 01-09-2015
Publisher: Springer US
Published in: NeuroMolecular Medicine / Issue 3/2015
Print ISSN: 1535-1084
Electronic ISSN: 1559-1174
DOI: https://doi.org/10.1007/s12017-015-8361-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer’s Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

NGF Expression in Reelin-Deprived Retinal Cells: A Potential Neuroprotective Effect

Structure, Distribution, and Function of Neuronal/Synaptic Spinules and Related Invaginating Projections

Restoration of Normal Cerebral Oxygen Consumption with Rapamycin Treatment in a Rat Model of Autism–Tuberous Sclerosis

KALRN Rare and Common Variants and Susceptibility to Ischemic Stroke in Chinese Han Population

Alpha-Linolenic Acid-Induced Increase in Neurogenesis is a Key Factor in the Improvement in the Passive Avoidance Task After Soman Exposure

Are Molecules Involved in Neuritogenesis and Axon Guidance Related to Autism Pathogenesis?